On April 8 2026, ANI Pharmaceuticals received final FDA approval for its abbreviated new drug application (ANDA) for Isosorbide Mononitrate Tablet USP, a generic version of the branded drug Monoket®. The product is available in 10‑mg and 20‑mg strengths and is indicated for the prevention of angina pectoris and other cardiovascular conditions.
The approval allows ANI to add a new product to its generics portfolio, which has historically generated steady cash flow that supports the company’s expansion into rare‑disease therapeutics. In the fourth quarter of 2025, the generics segment reported net revenues of $100.8 million, up 28.2 % from the same period in 2024, underscoring the segment’s role as a reliable revenue engine.
While the generic market for isosorbide mononitrate is competitive, the number of manufacturers is limited, giving ANI a modest opportunity to capture market share. The drug’s first FDA approval dates back to 1991, and the generic launch is expected to strengthen ANI’s position in a therapeutic area with a small number of competitors.
Nikhil Lalwani, President and CEO, said, "We are pleased to announce FDA approval and launch of Isosorbide Mononitrate Tablet USP, which highlights our efforts to bring limited‑competition products to market and ensure that our high‑quality products are readily accessible to our customers and patients in need." He added, "This launch reinforces the strength of our R&D capabilities and operational execution as well as our commitment to maintaining a steady cadence of new product launches."
The launch is part of ANI’s broader strategy to diversify its revenue base and strengthen its cash‑generating engine. The company is simultaneously accelerating its rare‑disease portfolio, with Cortophin Gel expected to account for roughly 60 % of total revenue in 2026. ANI plans to expand its rare‑disease organization by about 90 people to support this growth.
ANI’s fourth‑quarter 2025 results reflected robust performance, with earnings per share of $2.33 beating analyst expectations of $1.97 and revenue of $247.1 million surpassing the forecast of $232.37 million. The company’s financial health was rated "GREAT" by InvestingPro, and it has maintained a strong balance sheet while pursuing strategic acquisitions, such as the June 2024 purchase of Alimera Sciences for $381 million upfront, which added ILUVIEN® and YUTIQ® to its portfolio and contributed an estimated $105 million in pro‑forma 2024 revenues.
Looking ahead, ANI has guided 2026 total net revenues between $1.055 billion and $1.115 billion, with adjusted non‑GAAP EBITDA projected between $275 million and $290 million. The company’s focus on high‑margin generics and its expanding rare‑disease pipeline position it to sustain growth and maintain a healthy cash flow stream to fund future innovation.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.